Pulmonary hypertension is a life-threatening condition characterized by high blood pressure in the arteries of the lungs, causing difficulty breathing and limited physical activity. With this collaboration, Gossamer and Chiesi Group aim to drive global healthcare innovation by harnessing the potential of Seralutinib, demonstrating a shared commitment to addressing unmet patient needs on a global scale.
This collaboration taps into a growing global focus on lung health in the aftermath of the COVID-19 pandemic. According to research reports, PAH alone affects 15 to 50 individuals per million of the global population, and thus modern treatments like Seralutinib become vital for improving the quality of life for patients battling pulmonary hypertension.
This global collaboration and licensing agreement between Chiesi Group and Gossamer showcases a shared commitment from both companies to advance life-changing therapies for pulmonary hypertension patients globally. Further research and development of Seralutinib in PAH, PH-ILD & other indications will help save and improve the lives of millions of people suffering from these life-threatening conditions, said a top executive from Gossamer.
Elevating R&D beyond national borders enables both companies to pool resources, knowledge, and expertise to spur innovation in treating a disease that lowers the quality of life for the global affected patient population.
It is noteworthy that although Gossamer specializes in developing innovative therapies for pulmonary diseases, it focuses its resources extensively on the development and commercialization of Seralutinib. This partnership with Chiesi Group gives Gossamer access to invaluable international clinical resources to further expand its research and cater to international patient needs effectively.
This partnership reflects the evolving ecosystem of the biopharmaceutical industry, showcasing how collaborating on R&D efforts can pave the way for breakthrough therapies to tackle complex and rare diseases such as PAH and PH-ILD and improve global health outcomes.
Comments